Imagion Biosystems Ltd - Asset Resilience Ratio

Latest as of June 2020: 75.37%

Imagion Biosystems Ltd (IBX) has an Asset Resilience Ratio of 75.37% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$4.33 Million
≈ $3.06 Million USD Cash + Short-term Investments

Total Assets

AU$5.74 Million
≈ $4.06 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2019)

This chart shows how Imagion Biosystems Ltd's Asset Resilience Ratio has changed over time. Check IBX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Imagion Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Imagion Biosystems Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$4.33 Million 75.37%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$4.33 Million 75.37%

Asset Resilience Insights

  • Very High Liquidity: Imagion Biosystems Ltd maintains exceptional liquid asset reserves at 75.37% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Imagion Biosystems Ltd Industry Peers by Asset Resilience Ratio

Compare Imagion Biosystems Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
Cowealth Medical China Co.Ltd.
SHG:603122
Diagnostics & Research 2.25%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%

Annual Asset Resilience Ratio for Imagion Biosystems Ltd (2016–2019)

The table below shows the annual Asset Resilience Ratio data for Imagion Biosystems Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 69.82% AU$3.40 Million
≈ $2.41 Million
AU$4.87 Million
≈ $3.45 Million
-14.37pp
2018-12-31 84.19% AU$4.37 Million
≈ $3.09 Million
AU$5.19 Million
≈ $3.67 Million
-5.76pp
2017-12-31 89.94% AU$6.87 Million
≈ $4.86 Million
AU$7.64 Million
≈ $5.41 Million
+89.72pp
2016-12-31 0.23% AU$27.64K
≈ $19.56K
AU$12.14 Million
≈ $8.59 Million
--
pp = percentage points

About Imagion Biosystems Ltd

AU:IBX Australia Diagnostics & Research
Market Cap
$4.17 Million
AU$5.89 Million AUD
Market Cap Rank
#28888 Global
#1574 in Australia
Share Price
AU$0.01
Change (1 day)
-7.69%
52-Week Range
AU$0.01 - AU$0.05
All Time High
AU$8.60
About

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing th… Read more